A Randomized, Double-Blind, Dose-Ranging Study of INCB018424 Phosphate Cream in Subjects With Vitiligo
Phase of Trial: Phase II
Latest Information Update: 24 Oct 2018
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Vitiligo
- Focus Therapeutic Use
- Sponsors Incyte Corporation
- 23 May 2018 Planned End Date changed from 1 May 2020 to 1 Jul 2020.
- 23 May 2018 Planned primary completion date changed from 1 Jul 2018 to 1 Sep 2018.
- 08 May 2017 Status changed from not yet recruiting to recruiting.